Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer - Pfizer (NYSE:PFE), Merck (OTC:MKKGY)
Merck KGaA regains exclusive rights to develop, manufacture, and commercialize Bavencio (avelumab) Pfizer will exit its global partnership over the PD-L1 MAb on 30 June. Pfizer shares are down 0.24% at $40.30 on the last check Monday.
Published 2 months ago · Germany
News Articles
More
Filters
Filters
Time & Location
Sources are mostly out of (0)
Bias Distribution
100% of the sources are Center
C 100%
See less detail
